These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 27039149)

  • 21. Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy.
    Zamani P; Navashenaq JG; Teymouri M; Karimi M; Mashreghi M; Jaafari MR
    Life Sci; 2020 Jul; 252():117646. PubMed ID: 32272178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer.
    Füredi A; Szebényi K; Tóth S; Cserepes M; Hámori L; Nagy V; Karai E; Vajdovich P; Imre T; Szabó P; Szüts D; Tóvári J; Szakács G
    J Control Release; 2017 Sep; 261():287-296. PubMed ID: 28700899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment.
    Dumont N; Merrigan S; Turpin J; Lavoie C; Papavasiliou V; Geretti E; Espelin CW; Luus L; Kamoun WS; Ghasemi O; Sahagian GG; Muller WJ; Hendriks BS; Wickham TJ; Drummond DC
    Nanomedicine; 2019 Apr; 17():71-81. PubMed ID: 30654182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
    Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
    Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
    Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
    Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J; Lee A; Lu Y; Lee RJ
    Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formulation and optimization of idarubicin thermosensitive liposomes provides ultrafast triggered release at mild hyperthermia and improves tumor response.
    Lu T; Lokerse WJM; Seynhaeve ALB; Koning GA; Ten Hagen TLM
    J Control Release; 2015 Dec; 220(Pt A):425-437. PubMed ID: 26541464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human epidermal growth factor receptor-2 antibodies enhance the specificity and anticancer activity of light-sensitive doxorubicin-labeled liposomes.
    Li Q; Tang Q; Zhang P; Wang Z; Zhao T; Zhou J; Li H; Ding Q; Li W; Hu F; Du Y; Yuan H; Chen S; Gao J; Zhan J; You J
    Biomaterials; 2015 Jul; 57():1-11. PubMed ID: 25956192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
    Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP
    Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.
    Li Q; Lv S; Tang Z; Liu M; Zhang D; Yang Y; Chen X
    Int J Pharm; 2014 Aug; 471(1-2):412-20. PubMed ID: 24905776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
    Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
    Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance.
    Liao ZX; Chuang EY; Lin CC; Ho YC; Lin KJ; Cheng PY; Chen KJ; Wei HJ; Sung HW
    J Control Release; 2015 Jun; 208():42-51. PubMed ID: 25637705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
    Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
    Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of localized ultrasound-targeted microbubble destruction with doxorubicin liposomes in H22 mouse hepatocellular carcinoma model.
    Zhu F; Jiang Y; Luo F; Li P
    J Drug Target; 2015 May; 23(4):323-34. PubMed ID: 25609362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
    Gabizon AA; Patil Y; La-Beck NM
    Drug Resist Updat; 2016 Nov; 29():90-106. PubMed ID: 27912846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
    Shroff K; Kokkoli E
    Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
    Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
    Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery.
    Ding Y; Sun D; Wang GL; Yang HG; Xu HF; Chen JH; Xie Y; Wang ZQ
    Int J Nanomedicine; 2015; 10():6199-214. PubMed ID: 26491292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.